

EOR FURTHER TRAN A AD

JUN 14 1978

THE EFFECTS OF ACUTE ALTERATIONS IN HEMODYNAMICS, OXYGEN AVAILABILITY AND ACID-BASE BALANCE ON THE PERMEABILITY OF THE GASTRIC MUCOSA

ANNUAL PROGRESS REPORT (FOR THE PERIOD 1 OCT. 77 TO 30 SEPT. 78)

DATE OF REPORT May 24, 1978

BY

WALLACE P. RITCHIE, JR., M.D.

SUPPORTED BY US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND WASHINGTON, D.C. 20314

CONTRACT NO. DAMD 17-74-C-4014

UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE CHARLOTTESVILLE, VIRGINIA 22901

APPROVED FOR PUBLIC RELEASE: DISTRIBUTION UNLIMITED

THE FINDINGS IN THIS REPORT ARE NOT TO BE CONSTRUED AS AN OFFICIAL DEPARTMENT OF THE ARMY POSITION UNLESS SO DESIGNATED BY OTHER AUTHORIZED DOCUMENTS.

AD A 0 5 5 1 1 0

COPV

AU NO.

REPORT D	OCUMENTATION PAGE	READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER	may 78 2. GOVT ACCESSION	NO. 3. REGIPTEN T'S CATALOG NUMBER
TITLE (and Subtilia)		TYPE OF REPORT & PERIOD COVERED
The Effects of Acu Oxygen Availabilit the Permeability o	te Alterations in Hemodynamic y, and Acid-Base Balance in f the Gastric Mucosa •	Annual rogress Kepert. <u>1 Oct 77-30 Sep</u> 78 - 
7. AUTHOR(a)		8. CONTRACT OR GRANT NUMBER(+)
Wallace P./	Ritchie, Jr (15)	DAMD 17-74-C-4014
PERFORMING ORGANIZATIO	N NAME AND ADDRESS	10. PROGRAM ELEMENT, PROJECT, TASK
University of Virg Charlottesville, V	inia School of Medicine (	61102A 16 3A161102B71R 01.073
1. CONTROLLING OFFICE NAM	AE AND ADDRESS	12. REPORT DATE
U.S. Army Medical Frederick, Marylan	Research & Development Comman d 21701	d May 24, 1978 13. NUMBER OF PAGES 8
4. MONITORING AGENCY NAM	E & ADDRESS(II different from Controlling Offic	e) 15. SECURITY CLASS. (of this report)
		Unclassified
		154. DECLASSIFICATION DOWN GRADING
6. DISTRIBUTION STATEMENT Approved for public	(of this Report) c release, distribution unlim	ited
16. DISTRIBUTION STATEMENT Approved for public 17. DISTRIBUTION STATEMENT	(of this Report) c release, distribution unlim (of the abatract entered in Block 20, 11 different	ited
16. DISTRIBUTION STATEMENT Approved for public 17. DISTRIBUTION STATEMENT	(of this Report) c release, distribution unlim	ited from Report)
16. DISTRIBUTION STATEMENT Approved for public 17. DISTRIBUTION STATEMENT 18. SUPPLEMENTARY NOTES	(of this Report) c release, distribution unlim	ited (from Report)
16. DISTRIBUTION STATEMENT Approved for public 17. DISTRIBUTION STATEMENT 18. SUPPLEMENTARY NOTES	(of this Report) c release, distribution unlim	ited (rom Report)
16. DISTRIBUTION STATEMENT Approved for public 17. DISTRIBUTION STATEMENT 18. SUPPLEMENTARY NOTES	(of this Report) c release, distribution unlim (of the abatract entered in Block 20, 11 different	ited (from Report)
16. DISTRIBUTION STATEMENT Approved for public 17. DISTRIBUTION STATEMENT 18. SUPPLEMENTARY NOTES 19. KEY WORDS (Continue on rev	(of this Report) c release, distribution unlim (of the abatract entered in Block 20, if different (of the abatract entered in Block 20, if different	ited (rom Report)
16. DISTRIBUTION STATEMENT Approved for public 17. DISTRIBUTION STATEMENT 18. SUPPLEMENTARY NOTES 19. KEY WORDS (Continue on rev Bile acids inchem	(of this Report) c release, distribution unlim (of the abstract entered in Block 20, if different (of the abstract entered in Block 20, if different (a)	ited (from Report) (ber) (concersion muccess) acid=base
<ul> <li>16. DISTRIBUTION STATEMENT Approved for public</li> <li>17. DISTRIBUTION STATEMENT</li> <li>18. SUPPLEMENTARY NOTES</li> <li>19. KEY WORDS (Continue on rev Bile acids, ischem balance, prostagla</li> </ul>	(of this Report) c release, distribution unlim (of the ebstrect entered in Block 20, if different (of the ebstrect entered in Block 20, if different (a, hydrochloric acid, ulcero ndins, H <sub>2</sub> receptor antagonist	ited from Report) ber) genesis, mucosal acid-base s, tissue water
<ul> <li>16. DISTRIBUTION STATEMENT Approved for public</li> <li>17. DISTRIBUTION STATEMENT</li> <li>18. SUPPLEMENTARY NOTES</li> <li>19. KEY WORDS (Continue on rev Bile acids, ischem balance, prostagla</li> </ul>	(of this Report) c release, distribution unlim (of the abstract entered in Block 20, if different (of the abstract entered in Block 20, if different (a, hydrochloric acid, ulcero ndins, H <sub>2</sub> receptor antagonist	ited from Report) ber) genesis, mucosal acid-base s, tissue water
<ul> <li>16. DISTRIBUTION STATEMENT Approved for public</li> <li>17. DISTRIBUTION STATEMENT</li> <li>19. SUPPLEMENTARY NOTES</li> <li>19. KEY WORDS (Continue on rev Bile acids, ischem balance, prostagla</li> <li>20. ANSTRACT (Continue on rev Using a previous (Gastroent.68:699, 1</li> </ul>	(of the Report) c release, distribution unlim (of the obstract entered in Block 20, 11 different (of the obs	ited from Report) ber) genesis, mucosal acid-base s, tissue water ber) gastric mucosal ulcerogenesis this laboratory during the
16. DISTRIBUTION STATEMENT Approved for public 17. DISTRIBUTION STATEMENT 18. SUPPLEMENTARY NOTES 19. KEY WORDS (Continue on rev Bile acids, ischem balance, prostagla 20. AMSTRACT (Continue on rev Using a previou (Gastroent.68:699, 1 period covered by the genesis may be a con- application of 16.16	(of the ebstrect entered in Block 20, if different (of the ebstrect entered in Block 20, if different (of the ebstrect entered in Block 20, if different (of the ebstrect entered in Block 20, if different (a, hydrochloric acid, ulcero ndins, H <sub>2</sub> receptor antagonist sly described model for acute 975), studies carried out in e progress report indicate th sequence of uncompensated tis DM PGE2 significantly amelio	ited ited from Report) ber) genesis, mucosal acid-base s, tissue water ber) gastric mucosal ulcerogenesis this laboratory during the at acute gastric mucosal ulcero- sue acidosis; that the topical rates bile acid-ischemia induced
16. DISTRIBUTION STATEMENT Approved for public 17. DISTRIBUTION STATEMENT 18. SUPPLEMENTARY NOTES 19. KEY WORDS (Continue on rev Bile acids, ischem balance, prostagla 20. AffSTRACT (Continue on rev Using a previou (Gastroent.68:699, 1 period covered by the genesis may be a con- application of 16,16 acute mucosal lesion under the same circu the apparent permeab	(of the Report) c release, distribution unlim (of the obstract entered in Block 20, if different (of the obstract entered) (of the obstract entered) c and in Block 20, if different (of the obstract entered) (of the obstract entered) (of the obstract entered) c and that intraven mstances, perhaps as a conseq inity of the gastric mucosa t	ited from Report) genesis, mucosal acid-base s, tissue water gastric mucosal ulcerogenesis this laboratory during the at acute gastric mucosal ulcero- sue acidosis; that the topical rates bile acid-ischemia induced ous metiamide is cyto-protective uence of its ability to decrease o cations.

#### PROGRESS REPORT: CONTRACT DAMD17-74-C-4014

## I. TITLE OF RESEARCH CONTRACT:

The Effects of Acute Alterations in Hemodynamics, Oxygen Availability, and Acid-Base Balance on the Permeability of the Gastric Mucosa

## II. PRINCIPAL INVESTIGATOR

Wallace P. Ritchie, Jr., M.D., Ph.D. Department of Surgery University of Virginia School of Medicine Charlottesville, Virginia 22901 472-36-6392

### III. PERIOD COVERED: 1 October 1977 to 30 September 1978

## IV. PROGRESS REPORT

(1) Use of Radiolabeled Microspheres to Measure Gastric Mucosal Blood Flow. A principle goal of the current year has been to establish in our laboratory the capacity to estimate gastric mucosal nutrient blood flow using the radiolabeled microsphere technique originally described and validated by Archibald et al (Gastroent. 69:630, 1975). Briefly, the technique consists of injecting a pre-mixed solution of approximately 100,000 to 500,000 microspheres of uniform diameter, tagged with  $\gamma$  emitters of different energy spectra (<sup>51</sup>Cr, 141Ce, 85Sr), into the left ventrical. A reference sample is drawn at 10ml/min from the distal aorta for 80 seconds, beginning 10 seconds before injection. At the conclusion of the experiment the mucosa is sharply separated from the underlying muscular layers and dried at 60 C. The blood and tissue specimens are then dissolved in hot concentrated nitric acid to produce homogenous isotope solutions and are counted in a gamma counting system. Flow is calculated by comparing the activity of each isotope in the tissue with that in the reference sample of plasma as

> Flow (m1/Gm-min<sup>-1</sup>)= DPM mucosa (Gm) DPM/m1-min<sup>-1</sup> reference

Because the studies of Archibald et al indicate that submucosal shunting is minimal, even following damage to the gastric mucosa, this parameter has not been assessed.

In a series of preliminary studies, we have been able to confirm the observations of others with respect to the following: (1) the aminopyrine clearance technique for estimating mucosal blood flow underestimates microsphere flow by approximately 1/5 (1.3+0.3ml/min vs 6.2+1.2ml/min); (2) this discrepancy is reduced to approximately 1/3 during histamine stimulation; (3) the topical application of low concentrations of bile acid to the gastric mucosa increases

1

flow calculated either by the aminopyrine clearance technique (to 2.0+0.3ml/min) or by the microsphere technique (to 9.4+1/5ml/min); (4) under both circumstances, intraarterial infusion of low doses of vasopressin reduces flow in bile acid treated mucosa. We now feel sufficiently confident with the use of microspheres to employ this methodology on a routine basis.

(2) Differences in A-V Acid Base Balance During Acute Gastric Mucosal Ulcerogenesis. The combination of topical acid, topical bile acid, and nutrient mucosal ischemia is acutely ulcerogenic in the proximal stomach. The possibility that lesion formation under these circumstances is a consequence of inadequate tissue buffering of "back-diffused" intramucosal H+ was examined indirectly by measuring A-V differences in acid-base parameters across vascularized chambered wedges of canine gastric wall. Four groups of animals were studied during 5 sequential 15 minute periods. In each, the splenic artery and vein (which supply the wedge) were cannulated following in-situ splenectomy. The mucosae of Group A dogs (n=4) were exposed, during each period, to topical acid solution alone (ATS); of group B (n=4), to ATS containing 5mM Nataurocholate (TC); of group C (n=4), to ATS during splenic artery infusion with vasopressin (VP=0.01U/Kg-min); of Group D (n=4), to ATS+TC+VP. Indices evaluated= (1) sustemic arterial and splenic venous pH, pCO<sub>2</sub>, base deficit (BD) and  $[HCO_3]$ , (2) net H+ flux ( $\Delta$ H+), (3) aminopyrine clearance (AC), a measure of mucosal blood flow, (4) the degree of mucosal damage induced, the lesion index (LI, graded 0-5), and (5)  $HCO_3^-$  "output" (uEq/15min) by the wedge, calculated as  $[HCO_3^-]_V - [HCO_3^-]_A \times AC$ . The results/ 15 minutes (+SEM):

	ATS	ATS+TC	ATS+VP	ATS+TC+VP
$\Delta H+(uEq)$	-16+14	-395+22	-28+18	-375+25
HCO3 "output"	29+8	46+6	17+4	-14+5*
A-V Diff BD	+1.0+0.01	+0.9+0.5	+1.3+0.3	+5.5+0.8*
A-V Diff pH	0.05+0.01	0.07+0.01	0.12+0.01	0.21+0.03*
LI	0.2 + 0.1	0.4+0.4	0.2 + 0.1	4.8+0.3*

\*Significant difference vs. ATS, ATS+TC, ATS+VP

Systemic arterial pH was not significantly different between groups. Thus, during acute lesion formation, splenic venous HCO<sub>3</sub> "output" and pH were depressed, while splenic venous BD was increased, suggesting that mucosal ulcerogenesis may be a consequence of uncompensated tissue acidosis.

(3) Influence of Topical 16,16 DM Prostaglandin E2 on Bile Acid Induced Acute Gastric Mucosal Ulcerogenesis. It has been suggested that prostaglandins may be cyto-protective to the gastric mucosa under a variety of clinically applicable circumstances. The present study was undertaken to examine this possibility in the model outlined above. Two groups of dogs, each prepared with vascularized chambered ex-vivo wedges of proximal gastric mucosa, were studied during nine sequential 15 minute study periods. Group A (5 dogs) was exposed during periods 1-3, to topical acid test solution (ATS) during concomitant infusion of the splenic artery with 0.9% NaCl; during 4-6, to ATS+2mM sodium taurocholate (TC), again during splenic artery infusion with saline; and, during 7-9, to ATS+TC+ vasopressin (VP=5x10-3U/Kg-min. Group B (7 dogs) was studied in a similar fashion with the exception that the mucosa was pretreated with topical 16,16 DM PGE2, 5µg/Kg, 20 minutes prior to periods 1, 4, and 7. During each period, the following parameters of gastric mucosal function were evaluated: (1) net flux of H+ and Na+; (2) the electrical potential difference (PD); (3) the aminopyrine clearance (AC), a semiguantitative index of mucosal blood flow; and (4) the degree of mucosal damage induced, the lesion index (LI) graded on a 0-5 basis by an independent observer using photographs obtained at the end of each period in every dog. The results/15 minutes (+SEM):

	ATS	ATS+PGE2	ATS+TC	+PGE2	ATS+TC+VP	+PGE <sub>2</sub>
AH+ (µEq)	-24+8	-99+13	-160+21	-179+14	-264+24	-212+23
ANa+ (µEq)	+62+7	+166+24*	+118+9	+196+18*	+266+16	+171+12*
PD(mV)	-55+2	-58+2	-36+1	-44+2*	-18+1	-30+2*
AC(ml/min)	1.8+0.4	2.0+0.2	1.7+0.2	2.1+0.2	0.8+0.1	1.1+0.2
LI(0-5)	ō	ō	1 0	ō	4.4+0.4	1.7+0.4*

\*Significant difference vs. control

Conclusion: The topical application of 16,16 DM PGE<sub>2</sub> in large doses affords significant protection against bile acid-ischemia induced acute gastric mucosal ulcerogenesis. This protection is not accomplished by alterations in net H+ flux or in gastric mucosal blood flow. Rather, the data suggest that cyto-protection may be related to PGE<sub>2</sub> mediated maintenance of normal mucosal sodium homeostasis.

(4) Influence of the H<sub>2</sub> Antagonist, Metiamide, on Bile Acid Induced Acute Gastric Mucosal Ulcerogenesis. The present study was designed to evaluate the effect of metiamide, an H2 antagonist, on acute gastric mucosal damage produced by the combination of (1) bile acid induced "back-diffusion" of H+ and (2) concomitant gastric mucosal nutrient ischemia. Using vascularized, chambered wedges of proximal canine gastric wall, two groups of dogs were studied during 3 sequential periods. Control group A (9 dogs) was subjected to (1) topical acid test solution alone (ATS), (2) topical ATS+2mM taurocholic acid (TC), and (3) ATS+TC+vasopressin (VP), 5x10-3U/Kg-min infused into the splenic artery which supplies the wedge. Study group B was similarily treated, except that, in addition, metiamide (MET), 2µM/Kg-hr, was infused intravenously throughout the study. Parameters evaluated during each period included (1) net flux H+, Na+; (2) aminopyrine clearance (AC), a semiquantitative index of gastric mucosal blood flow; and, (3) the severity of mucosal damage, the lesion index (LI), graded 0-5 by an independent observer using photographs. Results (+SEM) per 15 minutes:

	TA	S	ATS+	TC	ATS+T	C+VP
	Control	Met	Control	Met	Control	Met
AH+ (uEq)	-21+8	-27+7	-231+21	-124+18*	-314+17	-211+25*
$\Delta Na + (uEq)$	+79+5	+68+7	+190+11	+111+8*	+315+19	+209+15*
AC(ml/min)	3.3+0.3	3.6+0.3	4.7+0.3	4.7+0.3	1.7+0.2	1.9+0.1
LI	- 0	ō	ō	ō	4.4+0.2	2.3+0.3*

\*P=or <0.005 vs. control

Conclusions: (1) Metiamide significantly protects against acute mucosal damage induced by bile acids and ischemia. (2) This protection is not mediated by alterations in gastric mucosal blood flow. (3) Rather, metiamide may be protective by virtue of its ability to decrease the apparent permeability of the gastric mucosa to cations.

(5) <u>Tissue Water Distribution in Bile Acid Treated Mucosa</u>. In 8 dogs, chambered wedges of proximal gastric wall were prepared as described above. An in-situ splenectomy was performed to reduce the distribution space of the extracellular water marker employed, <sup>14</sup>C-inulin, without compromising the blood supply to the wedge. The superior splenic artery and vein were cannulated. Acid test solution was introduced into the mucosal chamber, and the splenic artery was infused with 0.9% NaCl for 30 minutes. At the end of this time an aliquot of splenic venous blood and a sample of mucosa were obtained for plasma and tissue blanks.

A constant intraarterial infusion of 0.9% NaCl containing sufficient 14C-inulin to produce a specific activity in venous plasma of 20-100 times background was then begun. Venous plasma samples were obtained at 15 minute intervals and counted in a liquid scintillation system to ascertain when steady state conditions existed.

Once these had been achieved, the extracellular, intracellular, and total tissue water were calculated by methods described in detail in the current contract. Briefly, 100-200mg slices of mucosa were weighed and solubilized. A lml aliquot was pipeted into 9ml of triton-toluene base, permitted to dark attempt for 48 hours, and then counted for 20 minutes in a liquid scintillation counting system. Appropriate quench corrections were made. Extracellular water space was calculated by comparing plasma specific activity to tissue specific activity.

Total tissue water was determined by heating additional mucosal samples to dryness. Total tissue water was taken as the difference between the wet and dry weights of the samples. Intracellular water was calculated by subtracting the individual values obtained for extracellular water from the mean value of total tissue water obtained from the same experiment. Preliminary data indicate that acid peptic secreting mucosa exposed to topical acid contains 752+2µl of total water, 239+14µl of extracellular water, and, 509+14µl of intracellular water/mgm of tissue. The influence of topical bile acid application on the same parameters is now being assessed.

# V. PUBLICATIONS DURING THE CURRENT CONTRACT YEAR

Ritchie, W.P., Jr.: Bile acids, the "barrier" and reflux related clinical disorders of the gastric mucosa. Surgery 82:192-200, 1977.

Cherry, K.J., Jr., and Ritchie, W.P., Jr.: Methylprednosilone protects against bile acid induced acute gastric mucosal ulcerogenesis. Surgical Forum 28:355-357, 1977.

Ritchie, W.P., Jr., Nading, A., Shearburn, E.W., III: Relationship of transmural electrical potential difference to changes in gastric mucosal permeability to H+ and blood flow. Am J. Surg. 135:110-114, 1978.

Ritchie, W.P., Jr., CHerry, K.J., Jr., and Gibb, A.: Influence of methylprednisilone sodium succinate on bile acid induced acute gastric mucosal damage. Surgery. In Press.

DC Buff Section (3) INANNOUNCED (3) USTIFICATION (3) NY DISTRIBUTION/AVAILABILITY COPES HIST A ADL ST. 4 (2) 52 CIPU	NTIS	White Section
INANNOUNCED DISTIFICATION DISTIFICATION DISTIFICATION DISTRIBUTION/AVAILABILITY CORES	DC	Buff Section []
USTIFICATION	NANNOUNCE	0 ()
IY DISTRIBUTION/AVAILADILITY COPES HST 4 Art study i 82 Gene	USTIFICATION	
	Dist. A All	state of SP CIAL
		Section 1996 In Strate
A	A	